Lifeboat Foundation

In the summer of 2020, Keith Thomas dove into a swimming pool and became paralyzed from the chest down. He spent the next six months isolated in the hospital before joining a clinical medical trial that could make history for its use of groundbreaking Artificial Intelligence technology. Five chips were implanted into his brain which connects to a computer that can read his mind and send signals to parts of his body. Inside Edition Digital has more.

A team of environmental and molecular biologists at the Weizmann Institute of Science, working with a colleague from the Edmond and Lily Safra Children’s Hospital and another with The Hebrew University-Hadassah Medical School, all in Israel, has conducted a census of the immune cells that reside in the human body. The group describes their endeavor in a paper published in Proceedings of the National Academy of Sciences.

Prior research has shown that there are many kinds of immune cells in the human body and that they reside in different locations. Most if not all of them have been identified as well. But until now, it was not known how many of each type of cell exist in the average human body, how much room they take up or how much they weigh. In this new effort, the research team filled in that gap by conducting a three-pronged survey of immune cells in three types of average human bodies—a grown male, a grown woman and a child.

The three-pronged approached involved first studying available literature to obtain as much data as possible regarding the different types of immune cells. The second part involved conducting cell imaging to categorize cell phenotypes and complex immune cell types—a means of describing how much room different immune cells take up, wherever they may live. And the third part consisted of computational techniques to estimate cell numbers in different parts of the body, with which the team was able to calculate weights and mass.

Metabolites called nucleotides are the building blocks of DNA and can impact cancer’s sensitivity or resistance to chemotherapy and radiation in brain cancer. Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite, called GTP, controls responses to radiation and chemotherapy in an unexpected way.

“We learned that if you increase a cell’s GTP levels, it makes it really resistant to radiation or chemotherapy. Lowering GTP levels, the cell becomes much more sensitive,” said Daniel Wahl, M.D., Ph.D., associate professor of radiation oncology at Michigan Medicine and senior author of this paper.

Researchers have long known that levels of nucleotides like GTP control how fast DNA damage is repaired, which in turn controls sensitivity to therapies.

As long as people have been alive, they’ve wanted to stay alive. For centuries, explorers have searched for the fountain of youth. And today, scientists are hard at work researching technology that can extend the human lifespan, stop or reverse aging; and even preserve a terminally ill person indefinitely, until a cure for their disease is discovered. But what if — instead of preserving our *bodies* — we could preserve our *consciousness*; by uploading it to a powerful computer. This is called *mind uploading*. And one startup has developed a procedure to do exactly this. It’s scientifically sound, there’s a waiting list to participate, and the procedure — is one hundred percent fatal. Let’s find out why.〰
🙏 SUPPORT THE WHY FILES
🙏 https://www.patreon.com/thewhyfiles (Fun, Free Perks!)👽 BUY WHY FILES MERCH
👽 https://shop.thewhyfiles.com (Code: LIZZIDPEEPLE for 10% off first order)💬 CHAT WITH US ON DISCORD
💬 https://thewhyfiles.com/discord〰
🌐 OFFICIAL WEB SITE: https://thewhyfiles.com🕵️ Submit a topic, suggestion or just say hi:
🕵️ https://thewhyfiles.com/tips🎨 Have a product suggestion or want to design artwork for TWF?
🎨 https://thewhyfiles.com/merch📸 BE A WHY FILES MODEL (and get free stuff!)
📸 Send a photo of you/family/friends watching TWF.
📸 wearing TWF gear, using TWF merchandise:
📸 https://thewhyfiles.com/wild〰
🎧 THE PODCAST VERSION
🎧 https://thewhyfiles.com/podcast〰
⁍ TWF on SOCIAL (in order of importance)
⁍ https://www.reddit.com/r/TheWhyFiles/
⁍ https://twitter.com/OMGTheWhyFiles.
⁍ https://www.instagram.com/OMGTheWhyFiles.
⁍ https://www.tiktok.com/@thewhyfiles.
⁍ https://www.facebook.com/OMGTheWhyFiles〰
🐠 BETTER CHANNELS TO WATCH:
🐠 https://www.youtube.com/c/HecklefishMoriarty.
🤓 https://www.youtube.com/c/TheWhyFilesBackstage.
#science #future #technology

You’ve probably heard of CRISPR, the revolutionary technology that allows us to edit the DNA in living organisms. Biochemist and 2023 Audacious Project grantee Jennifer Doudna earned the Nobel Prize for her groundbreaking work in this field — and now she’s here to tell us about its next world-changing advancement. She explains how her team at the Innovative Genomics Institute is pioneering a brand new field of science — precision microbiome editing — that uses CRISPR in an effort to solve seemingly insurmountable problems like asthma, Alzheimer’s and climate change.
This ambitious idea is part of the Audacious Project, TED’s initiative to inspire and fund global change.

If you love watching TED Talks like this one, become a TED Member to support our mission of spreading ideas: https://ted.com/membership.

Continue reading “CRISPR’s Next Advance Is Bigger Than You Think” »

A study by the Global Antibiotic Research & Development Partnership and Innoviva Specialty Therapeutics found a single dose of a first-in-class oral antibiotic called zoliflodacin was as safe and effective as standard therapy for uncomplicated urogenital gonorrhea. NIAID contributed financial and scientific support to the development of zoliflodacin and applauds its non-governmental and private sector partners on successfully conducting the study. Read the NIH statement on these results: https://go.nih.gov/Wquuct

A single dose of a novel oral antibiotic called zoliflodacin has been found to be as safe and effective as standard therapy for uncomplicated urogenital gonorrhea in an international Phase 3 non-inferiority clinical trial, according to the Global Antibiotic Research & Development Partnership (GARDP), the study sponsor. Gonorrhea treatment options are increasingly limited due to antimicrobial resistance seen in Neisseria gonorrhoeae, the bacteria that cause gonococcal infection.

Because of the imperative to expand the gonococcal therapeutic pipeline, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has contributed financial and scientific support to the development of zoliflodacin and applauds its non-governmental and private sector partners on successfully conducting the Phase 3 study. This research has generated important new evidence for a field in urgent need of alternative therapeutic options. Specifically, zoliflodacin may offer an alternative to current therapy for uncomplicated urogenital gonococcal infection.

Continue reading “NIH Statement on Preliminary Efficacy Results of First-in-Class Gonorrhea Antibiotic Developed Through Public-Private Partnership” »

Tall 10-year-olds may be more at risk of developing an irregular heart rate in later life than their shorter counterparts, but less at risk of having a stroke.

By David Cox

A cancer drug in the final stages of clinical trials may be able to help treat a range of inflammatory diseases including gout, heart failure, cardiomyopathy, and atrial fibrillation, according to scientists at the University of Cambridge.

Their findings are published in the Journal of Clinical Investigation in an article titled, “PLK1 inhibition dampens NLRP3 inflammasome-elicited response in inflammatory disease models.”

“Unabated activation of the NLR family pyrin domain–containing 3 (NLRP3) inflammasome is linked with the pathogenesis of various inflammatory disorders. Polo-like kinase 1 (PLK1) has been widely studied for its role in mitosis,” wrote the researchers. “Here, using both pharmacological and genetic approaches, we demonstrate that PLK1 promoted NLRP3 inflammasome activation at cell interphase. Using an unbiased proximity-dependent biotin identification (Bio-ID) screen for the PLK1 interactome in macrophages, we show an enhanced proximal association of NLRP3 with PLK1 upon NLRP3 inflammasome activation. We further confirmed the interaction between PLK1 and NLRP3 and identified the interacting domains.”

Researchers hope dimeric IgA-based immunotherapy could be more precise, long-lasting, and less toxic than current anticancer treatments.